Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Study Identifier:
ALXN1210-NEPH-202
ClinicalTrials.gov Identifier:
NCT04564339
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete

Study Details

Medical Condition
  • Lupus
  • Unmapped
Study Drug
  • Drug: Ravulizumab
  • Drug: Placebo
Date
Jan 2021 - Apr 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Sex
Female & Male
Age
18 - 75 Years

Study Details

Medical Condition
  • Lupus
  • Unmapped
Study Drug
  • Drug: Ravulizumab
  • Drug: Placebo
Date
Jan 2021 - Apr 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years years
Requirements Information

Protocol Summary

The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).

Trial Locations

Location
Status
Location
Research Site
S. Gate, California, United States, 90280
Status
N/A
Location
Research Site
San Dimas, California, United States, 91773
Status
N/A
Location
Research Site
Santa Monica, California, United States, 90404
Status
N/A
Location
Research Site
Stanford, California, United States, 94305
Status
N/A
Location
Research Site
Orlando, Florida, United States, 32835
Status
N/A
Location
Research Site
Plantation, Florida, United States, 33324
Status
N/A